Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statemen

August 2022 Exhibit 99.1

Certain statements in this presentation

and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation,

including statements regarding our future financial condition, technology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of

success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different

from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the

uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVID-19 pandemic; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved

products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting

risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking

statements as predictions of future events. More information concerning AVITA Medical as well as the aforementioned risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most

recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and our most recent Transition Report on Form 10-KT period from July 1, 2021 to December 31, 2021. We are providing this information as of its date and do not undertake any

obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public

filings made after the date of this presentation. AVITA Medical's products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events. In

the United States, RECELL is approved for use in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational

device exemption granted by the FDA (and likewise limited by United States law to investigational use only). Legal Disclaimers

RECELL System: FDA approved for

the treatment of acute thermal burns Proprietary Spray-On SkinTM offers life changing benefits Point of care technology that is safe & effective Published health economic model demonstrating hospital cost savings Deep scientific and clinical

pedigree 2 randomized controlled trials and 1st PMA in burns in > 20yrs >15,000 patients, >330 publications and presentations Ongoing platform expansion: Multi-billion Dollar U.S. market opportunity Platform technology with numerous

adjacent applications PMA label expansion underway with PMA supplements for two indications in 2022 Proof of concept established for cell-based gene therapy and aesthetics Transforming Lives with Skin Regeneration * In the US, RECELL is approved for

acute thermal burns in patients > 18 years (("ATB") only (see www.avitamedical.com)). Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. Revolutionary

treatment using a patient's own skin for life-changing outcomes

One Platform. Endless Possibilities. In

the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. RECELL enables regeneration of healthy skin Patch of healthy

skin removed from patient Healthy skin processed using the RECELL System Autologous skin cells are sprayed on patient RECELL delivers healthy skin cells Free cells modulate and catalyze the healing process Technology platform could

potentially benefit a wide array of skin defects and wounds irrespective of etiology Vitiligo Burns / Scalds Scar Revision Infectious Disease Regenerative Dermatology Trauma Chronic Wounds Cancer Reconstruction Genodermatoses SKIN

Commercial Revenue Growth YoY of +39%

in the First Half of 2022 and +23% in the Second Quarter 2022 Soft Tissue Pivotal Trial: Topline Results Vitiligo Pivotal Trial: Enrollment & 6-month Follow-up Complete FDA Approval & Launch of New "Ease of Use" RECELL

Device PMDA Approval of Burns in Japan and cases completed Initial Proof of Concept for EB and Rejuvenation (Delivery of Modified Skin Cells in Suspension) Value Creation Quarters referenced in calendar year. As of January 1, 2022 Avita Medical is

reporting on a calendar year basis. Recent Key Accomplishments Projected Key Milestones Top Line Results and Vitiligo FDA Submission / Vitiligo Commercial launch Soft Tissue FDA Submission / Soft Tissue Commercial Launch Reimbursement &

Commercial Launch of Burns in Japan FDA Meeting Regarding IND Enabling Studies (EB & Rejuvenation) H2 '22 / H2 '23 H2 '22 H2 '22 / H2 '23 H2 '22

Development Pipeline and Growth

Innovation New Device: Improved Ease of

Use New Device: Fully Automated INDICATION DISCOVERY FEASIBILITY PIVOTAL APPROVAL LAUNCH Regenerative Therapeutics - Wounds & Dermatology (Current Platform) Acute Thermal Burns (U.S.) RECELL Japan Vitiligo (U.S.) Soft Tissue

Reconstruction (U.S.) Early-Stage Research Programs Epidermolysis Bullosa Rejuvenation Focused Pipeline with Strong Growth Potential In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by

United States law to investigational use; or (2) otherwise prohibited. CONCEPT DESIGN APPROVAL SUBMISSION Focused Effort on Business Development to Supplement Pipeline LAUNCH

EXISTING PLATFORM NEW PLATFORMS: CELL

BASED GENE THERAPY > $22 Billion in Combined TOTAL ADDRESSABLE MARKET Market Opportunity of Pipeline Exceeds $22 Billion Skin cells are genetically modified ~$6.8B Opportunity ~$15.8B Opportunity Burns Soft Tissue Vitiligo Epidermolysis Bullosa $

Current Platform: Efficacy is Well

Demonstrated Highly De-risked Pipeline with >15,000 Patients Treated Globally In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2)

otherwise prohibited. Patients (in Published Studies) Number of Publications & Presentations ACUTE WOUNDS (Including Thermal Burns) 1,852 255 DEFECTS/ VITILIGO 453 58 CHRONIC WOUNDS 143 19 A Common Goal: Full Skin Restoration

(Re-epithelialization and Re-pigmentation) PRODUCT IS WELL STUDIED

Thermal Burns: U.S. Target Market

Expanded to Include Small Burns and Outpatient Outpatient Pass Through Code Opens Doors to Small Burns and Expands Serviceable Market Opportunity Total Annual Burns in the U.S. Severe Burns (as defined as burns > 5% Body Surface Area that may

require grafting) Target: Severe Burns Treated at Burn Centers (Both In and Outpatient) ~$260 Million SAM >$600 Million TAM Patient Funnel and Addressable Market ~25K ~80K ~486K PATIENTS PATIENTS PATIENTS ($ 000s) Quarter Ended Strong U.S. RECELL

New Ease of Use Device FDA Approved

& Launched * Market Research March 2020 HCPs Only 1 Set of Hands Required in the Sterile Field; Steps Reduced By 33% Reduced number of steps New Device Simplified Process Improved Usability 94% of surveyed users of the RECELL System believe it

will reduce their workload/allow them to perform other duties*

Furue M, Yamazaki S, Jimbow K,

Tsuchida T, Amagai M, Tanaka T et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multi-center, hospital-based study. J Dermatol. 2011 April; 38(4):310-20, Japan Health System Review, 2018. Additional

estimates based on data from 2016 JSBI National Burns Repository, https://injuryprevention.bmj.com/content/26/Suppl_2/i36#F2 and Cosmotec estimates Approval of Burns Received in Japan Incidence of Burns Needing Medical Treatment in Japan Severe

Burns (defined as hospital admissions of burns that may require grafting) Target: Severe Burns Treated at Burn Centers ~1,400 ~6,000 ~250,000 PATIENTS PATIENTS PATIENTS BACKGROUND Reimbursement and Commercial Launch Anticipated in Q4 '22

PATIENT FUNNEL - BURNS ADDRESSABLE MARKET INDICATION: Burns Additional Indication(s) to Follow Based on U.S. Pivotal Clinical Data LAUNCH: Following Ministry of Health, Labour, and Welfare (MHLW) decision on reimbursement pricing, anticipated Q4

'22 AVITA Medical Commercial Partner: COSMOTEC, an M3 Company

Soft Tissue Repair Will Expand the

Burns Business to Encompass All Acute Wounds In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United

States, RECELL is not approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved. >4.5M patients TOTAL MARKET >140K TOTAL ADDRESSABLE MARKET SERVICEABLE AVAILABLE MARKET >65K

patients patients RECELL eligible procedures at high volume sites RECELL eligible trauma procedures OPPORTUNITY ESTIMATION SAM $450 Million TAM $1 Billion Open wounds presented at the Emergency Department Poster: Use of regenerative suspension in

the treatment of a complex de-gloving injury. Ian M Smith, Female, pregnant 28-year-old who suffered from a de-gloving Injury POST DEBRIDEMENT OF INJURY 6 MONTH POST-RECELL TREATMENT

Soft Tissue Synergies with Current

Commercial Burn Focus In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not

approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved. ~50% of Burn Centers are also Level 1 / Level 2 Trauma Centers Expanded Acute Wounds Sales Team Will Target a Total of 366

Centers Reimbursement in Place Able to leverage existing CPT & Outpatient C Code 136 Burn Centers (Current Target) +230 High Volume Trauma Centers (Future Expansion) Same Treatment Protocol to Burns Consistent treatment protocol across acute

injuries Same Unmet Needs as Burns Reduction of donor site morbidity & donor site requirements are top unmet needs Large opportunity that leverages existing burns infrastructure

Soft Tissue Indication on Track for

FDA Submission In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. Patient treated for necrotizing fasciitis

Photos courtesy of Kevin Foster, Valleywise Health Medical Center. Patient treated under Compassionate Use Program IDE13053 TREATMENT DAY 1 YEAR POST-RECELL TREATMENT FDA Submission Expected in H2 '22 with Approval in H2 '23 As seen with

burns treatment with RECELL, the study confirms use of less donor skin relative to the standard of care control (conventional skin grafting). Within-subject comparisons (treatment site healing and donor site size) Effectiveness Data Preliminary

review of adverse events shows consistency with prior RECELL experience Safety Data

Vitiligo: Debilitating Disease with

a Large Market Opportunity Advances in Vitiligo: An Update on Medical and Surgical Treatments. A. Dillon, et al. J Clin Aesth Derm. 2017. Willingness-to-Pay and Quality of Life in Patients with Vitiligo. Radtke, et al. BJD. 2009. UNADDRESSED PATIENT

POPULATION Up to 2% of the population affected Vitiligo impacts quality of life (QoL) - 25% of patients with vitiligo reported a DLQI >10, which indicates severe QoL reductions, compared with 34% in psoriasis patients In the U.S., RECELL is

approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. OPPORTUNITY ESTIMATION Concentrated HCP base: Estimating <1,000 procedural

dermatologists and plastic surgeons with interest in treating vitiligo SAM $750 Million TAM $5.2 Billion 4.5M (range 3-6.5 million) TOTAL MARKET 1.3M TOTAL ADDRESSABLE MARKET SERVICEABLE AVAILABLE MARKET 188K Estimated number of eligible patients at

target call points Prevalence of Vitiligo in the United States

Blinded Within-Subject Study to

Evaluate the Safety & Effectiveness of RECELL for Repigmentation of Stable Vitiligo Study 6-month follow-up completed FDA Submission expected in H2 '22 Approval expected in H2 '23 New Vitiligo Automated Device in development Vitiligo

Indication on Track for FDA Submission *NB-UVB protocol per Vitiligo Working Group recommendations JAAD 2017. In the United States, RECELL is not approved for treatment of vitiligo. Patient from a Prior Study at 6 MONTHS RECELL-treated area was 100%

re-pigmented RECELL treated Negative Control Komen L, Vrijman C, Tjin EP, Krebbers G, de Rie MA, Luiten RM, van der Veen JW, Wolkerstorfer A. Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and

piebaldism patients: a randomized controlled pilot study. Journal of the American Academy of Dermatology. 2015 Jul;73(1):170-2. POTENTIAL RECELL BENEFITS For Stable Vitiligo: Segmental & Non-Segmental Durable: One-time treatment KEY

RECELL Case: Repigmentation of the

Nipple-Areola Complex Yu et al. Repigmentation of nipple-areola complex after RECELL treatment on breast vitiligo. Journal of Cosmetic Dermatology, 2021 In the United States, RECELL is not approved for use with patients suffering vitiligo.

Established Track Record in Vitiligo: 1,000 patients treated internationally & 12 peer-reviewed publications showing positive outcomes Before RECELL 12 months After RECELL 23 year old female with vitiligo. Donor skin was harvested

from adjacent unaffected areas. Depigmented epidermis was removed using dermabrasion. The cellular suspension was then sprayed on both the recipient and donor areas (expansion ratio ranged from 1:20-1:40).

RECELL in Genetic Skin Defects and

Rejuvenation CURRENT PLATFORM FUTURE PLATFORM Treatment using RECELL for harvesting and direct reintroduction of the patient's own healthy skin cells RECELL as a platform for treatment using the patient's corrected skin cells Patch of

healthy skin removed from patient Healthy skin processed using the RECELL System Autologous skin cells are sprayed on patient Skin processed using the RECELL System Patch of skin removed from patient Enhanced autologous skin cells are reintroduced

to patient Gene editing for debilitating orphan skin disorder Molecular reversal of aging for skin rejuvenation Skin cells are genetically modified In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either

(1) limited by United States law to investigational use; or (2) otherwise prohibited.

Cell and Gene Therapy Development

Activity Program Objective: Optimize Spray-On Skin Cells with modified skin cells and establish IND-readiness Proof of Concept FDA Interaction IND-enabling Studies First-in-human (IND) Four key steps

1. Has et al, "Consensus

reclassification of inherited epidermolysis bullosa and other disorders with skin fragility." Br J of Dermatology. 2020. Range 1,100-2,500. 2. DEB prevalence estimated as 6/million. RDEB estimated to be approximately half of DEB prevalence =

3/million. Range: 1.35- 8/million. Fine et al, "Epidemiology of Inherited Epidermolysis Bullosa " JAMA, 2016. 3.. Luxturna (gene therapy for a rare, inherited retinal disease that can lead to blindness) was priced at $850,000 for a

population between 1000-2000 patients in US. Zolgensma for spinal muscular atrophy is priced at $2.1 million Sizeable Market Opportunity Estimated in EB, Given Orphan Pricing Potential ~$840M target US market opportunity, assuming $850,0004 per

patient / treatment 25-50,000 people 1980 TOTAL ADDRESSABLE MARKET 990 patients patients Patients with RDEB sub-type2 US Prevalence of Dystrophic EB (DEB)1 OPPORTUNITY ESTIMATION TAM $840 Million US Prevalence of Epidermolysis Bullosa POTENTIAL

COMPETITIVE ADVANTAGES Suspension is potentially more cost effective to generate, transport and apply vs cultured sheet grafts iPSC-based technology enables banking of cells for future treatments Ex vivo gene editing of skin cells has a safety

advantage over in vivo gene therapeutics

100 m Skin Regeneration from

Corrected Autologous Skin Cell Suspension Immunocompromised mouse model Full-thickness injury created Recapitulated human dermis Application of corrected cells Correction of RDEB Single-Site Mutation In Vivo Evaluation of Gene-corrected Skin Cells

New, healthy skin regenerated from iPSCs Successful reverse-differentiation (induced pluripotency) and gene correction of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Skin Cells Image courtesy of Gates Center for Regenerative Medicine,